Business Wire

ANEXT Bank Reports a Surge in Regional and Global Presence Among Its MSME Customers

Share

ANEXT Bank, a digital wholesale bank incorporated in Singapore and a wholly-owned subsidiary of Ant International, today reported a notable increase in regional and global presence among its micro, small and medium enterprises (MSMEs) customers. This is on the back of more than 2-fold growth in its total customer base over the past 12 months.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240605859058/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

Facilitating MSMEs’ Business Expansion Regionally and Beyond

The bank observed a 6-fold year-on-year increase in the total amount of cross-border transactions facilitated for its increasing customer base from the region and beyond. The highest growth in the bank’s cross-border transactions was seen among MSMEs in the wholesale and retail trade, professional services, and information, communication, and technology sectors, aligning with Singapore's robust status as a global trade and financial hub. Furthermore, ANEXT Bank customers exhibited an expanding regional and global presence, with operations extending beyond Singapore into key markets such as the Chinese mainland, Hong Kong SAR, the United States and other Southeast Asian countries.

In addition to Singapore MSMEs expanding regionally and globally, ANEXT Bank saw a notable increase in the number of Foreign Business Owners (FBOs) with businesses incorporated in Singapore. As of 31 May 2024, nearly 31% of the bank’s customers are FBO from 78 nationalities such as from the Chinese mainland, Indonesia, Japan, Malaysia and South Korea. Through its embedded finance partners, ANEXT Bank is also serving an increasing number of foreign-incorporated businesses.

“It is heartening to witness how MSMEs are growing beyond their markets, especially micro and small businesses. Internationalisation is no longer a growth strategy limited to large corporations – through technology and innovation, MSMEs can now easily access global markets. As a digital bank headquartered in Singapore, we are well positioned to support when they are open to doing business with the world,” said Ms. Toh Su Mei, CEO of ANEXT Bank. “It takes grit and openness to grow beyond the familiar. We share that same spirit with MSMEs. As we celebrate two years of delivering innovative digital financial services, we remain committed to supporting more MSMEs embrace new possibilities and achieve their global aspirations.”

Serving the Underserved MSMEs

As of 31 May 2024, 69% of ANEXT Bank’s customers are micro businesses. Breaking down by product categories, 56% of loan customers and 80% of deposit customers are micro businesses. Over the past two years, 31% of ANEXT Bank’s customers started banking with the bank during their start-up stage.

From setting up a multi-currency business account for local and overseas transfers with no minimal balance, getting fuss-free unsecured financing with flexible repayment options, and investing with a fixed deposit account from just US$5,000 for as short as one month, all these can be easily achieved within minutes.

In the most recent financial year ending 31 December 2023, ANEXT Bank achieved remarkable financial milestones. The "loans to customers" surged by 434%, reaching S$222 million, while the "deposits balance" increased by approximately 368%, totalling S$295 million. Additionally, ANEXT Bank reported S$24.5 million in gross income, highlighting its robust ability to generate revenue from primary banking activities and demonstrating significant progress towards its mission of driving financial inclusion.

About ANEXT Bank

Incorporated in Singapore and regulated by the Monetary Authority of Singapore, ANEXT Bank is a digital wholesale bank providing innovative digital financial services to empower local and regional micro, small and medium enterprises (MSMEs) to future-proof their businesses through digital adoption, sustainable practices and global expansion.

Through continuous technology-driven innovation, ANEXT Bank is dedicated to accelerating fintech development and financial inclusion in Singapore and the region. Adopting an open and collaborative approach, ANEXT Bank believes in joining hands with industry partners and public sector agencies to provide SMEs with financial services that are simpler, safer and more rewarding.

ANEXT Bank is a wholly-owned subsidiary of Ant International.

For more information on ANEXT Bank, please visit www.ANEXT.com.sg.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Eric Tey
Ant International
eric.tey@antgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Airway Therapeutics Wins 2024 ATS Whitsett Award for Abstract of Positive Phase 1b Results of Zelpultide Alfa in Preterm Neonates at Risk of Bronchopulmonary Dysplasia24.6.2024 12:30:00 EEST | Press release

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced today it received the Whitsett Award for highest scoring abstracts from the Neonatal and Developing Lung Executive Committee at the American Thoracic Society (ATS) 2024 International Conference. The abstract is titled “Randomized Blinded Phase 1b Study Demonstrates Safety and Tolerability of Zelpultide Alfa (rhSP-D) in Preterm Neonates at High Risk for the Development of Bronchopulmonary Dysplasia (BPD).” Thirty-seven infants, born at 23 weeks to 28 weeks and 6 days, were enrolled in the study in the US and Europe. No dose limiting toxicities were found while indications of efficacy were observed. As many as 2.5 million very preterm infants globally are at risk of developing BPD from lung damage caused by mechanical ventilation and oxygen support. Babies who develop BPD can suffer life

REPLY: AIRA Challenge 2024 Prize awarded to Roboverse Reply for Mobile Robot Control via VR Glasses24.6.2024 11:00:00 EEST | Press release

Roboverse Reply, specialises in integrating Robotics and Reality Capture with Mixed Reality, has won the Advanced Industrial Robotic Applications (AIRA) Challenge for the second time in a row. The competition invited world-leading experts to develop innovative solutions for enabling the remote control of mobile robots during autonomous inspections in production environments. Roboverse Reply’s platform demonstrates how Artificial Intelligence and human expertise can be combined to tackle challenging industrial tasks in real-world applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624606163/en/ Roboverse Reply, specialises in integrating Robotics and Reality Capture with Mixed Reality, has won the Advanced Industrial Robotic Applications (AIRA) Challenge for the second time in a row. (Graphic: Business Wire) The final of the AIRA Challenge took place for the second time at ACHEMA, the world's largest trade fair fo

Takeda Announces Approval of LIVTENCITY ® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies24.6.2024 10:00:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW)for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies.4 LIVTENCITY is the first and only post-transplant anti-CMV treatment approved in Japan that targets and inhibits pUL97 kinase and its natural substrates.1 “We are pleased by the approval of LIVTENCITY in Japan, which will provide the transplant community with a new option for treatment of post-transplant CMV infection in patients refractory to other therapies,” said Yasushi Kajii, Head, R&D Japan Region at Takeda. “A diagnosis of CMV infection can be particularly challenging for patients, and serious complications such as increased organ rejection and hospitalization rates can occur, when not successfully treated. We believe LIVTENCITY has the potential to help address the challenges faced by people with post-transplant CMV and

Megaport and Lufthansa Systems Announce Landmark Partnership to Accelerate Airline Digital Transformation24.6.2024 09:00:00 EEST | Press release

Megaport Limited (ASX: MP1) (“Megaport”), the global leading Network as a Service (NaaS) provider, and Lufthansa Systems, a leading aviation IT provider, today announced a new partnership that will accelerate digital transformation in the aviation industry. The strategic partnership will see Lufthansa Systems leverage Megaport’s global Software Defined Network (SDN) to securely and reliably move the global aviation cloud from a single cloud to multiple clouds by moving core routing from cloud to Megaport. Megaport will also facilitate a secure aviation customer landing zone to expedite peering with other airlines and exchanging data. Lufthansa Systems provides IT services to over 350 airlines worldwide. Its Global Aviation Cloud initiative aims to virtualise mission-critical airline applications and transition them to the cloud. Using Megaport’s private connectivity from resilient data centres, virtual firewalls, and virtual routing, Lufthansa Systems can securely and reliably connect

Seroba and Kurma Partners Announce Complementary Series B Funding for Vico Therapeutics totaling €65.8 million ($70.7 million)24.6.2024 09:00:00 EEST | Press release

Seroba, an European life sciences venture capital firm headquartered in Dublin, with offices in Paris and Milan, and Kurma Partners, a key European Venture Capital firm financing innovation in Healthcare and Biotechnology, from pre-seed to growth capital, based in Paris and Munich, announced today the completion of the second closing part of Series B financing round of Vico Therapeutics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240623484065/en/ Vico Therapeutics B.V. is a clinical-stage genetic medicines company developing therapies for severe neurological diseases. Its lead program VO659 is currently in a Phase 1/2a clinical study of patients with spinocerebellar ataxia types 3 and 1 and Huntington’s disease, devastating neurodegenerative diseases for which there are currently no disease-modifying treatments available. Seroba joined the consortium of investors leading the planned second closing of the Series B financi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye